June 17, 2009 (FinancialWire) — On June 12, Ivivi Technologies, Inc. (NASDAQ: IVVI) received a delisting notice from the staff of The NASDAQ Stock Market.

Previously, the company received a letter from NASDAQ, pursuant to which the Staff notified the company that the company was not in compliance with NASDAQ Listing Rule 5550(b) (formerly NASDAQ Marketplace Rule4310(c), which requires the company to have a minimum of $2,500,000 in stockholders’ equity or $35,000,000 market value of listed securities or $500,000 of net income from continuing operations for the most recently completed fiscal year or two of the three most recently completed fiscal years. On March 18, 2009, the company provided the Staff with a specific plan to achieve and sustain compliance with all the NASDAQ Capital Market listing requirements, including a time frame for completion of the plan. Based on the Staff’s review and the materials submitted by the company, the Staff granted the company’s request for an extension to comply with NASDAQ Listing Rule 5550(b).

On June 12, 2009, the company received a letter from the Staff (the “NASDAQ Letter”) pursuant to which the Staff notified the company that it had determined that the company did not meet the terms of the plan submitted to NASDAQ. In particular, the company failed to achieve a compliant stockholders’ equity balance as required by NASDAQ. As a result, unless the company requests an appeal of this determination to a NASDAQ Hearings Panel (the “Panel”), trading of the company’s common stock will be suspended on the NASDAQ Stock Market at the opening of business on June 23, 2009, and a form 25-NSE will be filed with the Securities and Exchange Commission (the “SEC”), which will remove the company’s securities from listing and registration on The NASDAQ Stock Market.

The company is considering whether to appeal the Staff’s determination to the Panel, pursuant to the procedures set forth in the NASDAQ Listing Rule 5800 Series. Any request for a hearing, however, must be received by NASDAQ’s hearings department no later than 4: 00 p.m. (eastern time) on June 19, 2009 together with payment of an appeal fee. If the company were to timely appeal the Staff’s determination, the delisting of the company’s securities would be stayed pending the Panel’s decision. Although the company is considering whether to appeal the Staff’s determination to the Panel, there can be no assurance that the company will request a hearing or if the company were to request a hearing, that the company would prevail.

If the company does not appeal the Staff’s determination to the Panel, the company’s securities will not be immediately eligible to trade on the OTCBB or in the Pink Sheets. The securities may become eligible if a market maker makes application to register in and quote the security in accordance with SEC Rule 15c2-11, and such application (a “Form 211″) is cleared. Only a market maker, not the company, may file a form 211. Accordingly, there can be no assurance that the securities would become eligible to trade on the OTCBB or in the Pink Sheets on a timely basis or at all.

Based in Montvale, NJ, Ivivi Technologies, Inc. is a medical technology company focusing on designing, developing and commercializing its proprietary electrotherapeutic technology platform.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.